Skip to main content
. 2024 Jan 4;15:275. doi: 10.1038/s41467-023-44237-4

Fig. 7. Characterization of DCAF1-based PROTACs in cells resistant to VHL or CRBN-mediated targeted protein degradation.

Fig. 7

a Schematic illustration of examples of intrinsic and acquired resistance mechanisms to targeted protein degradation (TPD). b 768-O cells treated for 2 h with DBr-1, VZ185, and dBRD9 at various doses. Shown is the change of relative BRD9 abundance normalized to the DMSO control. Data represents average ± standard deviation of n = 3 replicates and calculated DC50 values of BRD9 are displayed. c Immunoblot analysis of TMD8 WT and TMD8 CRBN resistant cells after 0.1 µM CBt and 1 µM DBt-10 treatment for 24 h. d Viability measured by CellTiter-Glo for CBt, Ibrutinib (Ibru), BTKi (17) and DBt-10 in WT (solid) vs CRBN resist. (dotted) TMD8 cells. Data represents mean ± standard deviation from n = 3 replicates. Source data are provided as a Source Data file.